ProQR Therapeutics N.V. logo
ProQR Therapeutics N.V. PRQR
$ 1.55 0.65%

Annual report 2025
added 03-21-2026

report update icon

ProQR Therapeutics N.V. Income Statement 2011-2026 | PRQR

Annual Income Statement ProQR Therapeutics N.V.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - - - 68.7 M 188 M 291 M 454 M 85 M 96.9 M 123 M 223 M - - -

Shares

- - - - 64.2 M 41 M 41 M 34.1 M 25.4 M 23.3 M 23.3 M 11.1 M - - -

Historical Prices

1.54 1.4 2.38 1.55 1.07 4.57 7.09 13.3 3.35 4.05 4.34 18.8 - - -

Net Income

- - - - -61.7 M -46.6 M -56.5 M -36.9 M -43.6 M -39.1 M -20.8 M -12.1 M -3.25 M - -

Gross Profit

- - - - - - - - - - - 313 K - - -

Operating Income

- - - - -57.2 M -42.4 M -57.4 M -36.3 M -40.5 M -39.6 M -27 M - - - -

Interest Expense

929 K 1.08 M 1.2 M - 3.4 M 2.04 M - - - - - - - - -

EBITDA

- - - - -57.2 M -42.4 M -57.4 M -36.3 M -40.5 M -38.5 M -26.6 M -16.3 M -3.19 M - -

Operating Expenses

59.8 M 50 M 41.4 M 69.5 M 59.6 M 51.8 M 59.4 M 42.1 M 42 M 39.8 M 27 M 16.5 M - - -

General and Administrative Expenses

- - - - 17.4 M 13.7 M 12.9 M 12.5 M 10.8 M 9.48 M 6.84 M 6.51 M 786 K - -

All numbers in EUR currency

Quarterly Income Statement ProQR Therapeutics N.V.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - 71.4 M 71.2 M 68.3 M 66.1 M 50.8 M 50.2 M 50.1 M 50 M 49.9 M 47.4 M 38.9 M 38.9 M 38.9 M - 33.4 M 31.9 M - - - 24 M - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - -14.4 M -18.2 M -15.1 M -15.8 M -12.6 M -13.2 M -13.2 M -4.12 M -16.1 M -18.6 M -12.2 M -11.7 M -14.2 M - -5.99 M -7.4 M - - - -11.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - 1.23 M 239 K 872 K 243 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - -16.9 M -17.3 M -14.6 M -13.2 M -12.1 M -11.7 M -10.9 M -3.36 M -16.5 M -17.4 M -13.4 M -11.8 M -14.7 M - -5.92 M -7.67 M - - - -10.2 M - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - -16.9 M -17.3 M -14.6 M -13.2 M -12.1 M -11.7 M -10.9 M -3.36 M -16.5 M -17.4 M -13.4 M -11.8 M -14.7 M - -5.92 M -7.67 M - - - -10.2 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - 18.3 M 17.8 M 15.7 M 13.9 M 12.2 M 11.9 M 11.1 M 12 M 16.7 M 17.8 M 14 M 12.4 M 15.2 M - 8.88 M 8.64 M - - - 10.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - 4.91 M 5.32 M 4.59 M 4.12 M 3.34 M 3.51 M 2.81 M 3.45 M 3.92 M 3.92 M 2.9 M 2.88 M 3.19 M - 2.58 M 2.65 M - - - 2.89 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

The income statement is one of the three key financial reports of a company ProQR Therapeutics N.V. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
$ 3.44 2.99 % $ 303 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 218.06 -1.72 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amgen Amgen
AMGN
$ 349.77 0.57 % $ 188 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.23 -1.38 % $ 899 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.6 0.76 % $ 6.06 B irlandaIrlanda
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Inventiva S.A. Inventiva S.A.
IVA
$ 6.08 5.19 % $ 138 M franceFrance
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.4 2.19 % $ 357 M britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.63 0.77 % $ 16.5 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 11.19 1.91 % $ 461 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.42 4.25 % $ 734 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.82 -4.08 % $ 3.29 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA